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Corticosteroids have been used in bronchopulmonary dysplasia prevention because of their antiinflammatory effects.
Among their effects is a decrease in the incidence of bronchopulmonary dysplasia. However, short- and long-term side
effects have been detected in preterm newborns.
PURPOSE: To analyze the effects of corticosteroids on bronchopulmonary dysplasia, length of stay, mortality, growth,
as well as the adverse effects in very low birth weight newborns between 10 and 14 days of life and dependent on mechanical
ventilation.
METHODS: Cohort study. All newborns with a birth weight under 1500 g, mechanical ventilation-dependent between
10 and 14 days of life, during the period January 2000 and June 2001 were included (n = 38). They were divided into 2
groups: Group I with corticosteroids (n = 16) and Group II without corticosteroids (n = 22). Dexamethasone administration:
from the 10th day of life, d1 – d3, 0.3 mg/kg/d; d4 – d6, 0.2 mg/kg/d; d7 – d9, 0.1 mg/kg/d. Respiratory evolution,
bronchopulmonary dysplasia (oxygen dependence at 28 days of life), growth pattern and the presence of adverse effects
were analyzed.
RESULTS: The incidence of bronchopulmonary dysplasia was 6.5% (Group I) and 30% (Group II), P = .07. A decrease
in growth was detected in Group I compared with Group II (change in weight: Group I — 47 g/week, Group II — 85.5 g/week,
P = .06; change in head circumference: Group I — 0.75 cm/week, Group II — 1 cm/week, P = .05).
CONCLUSION: Use of corticosteroids in very low birth weight infants dependent on mechanical ventilation during
the first 10 to 14 days of life did not affect the respiratory evolution and occurrence of bronchopulmonary dysplasia, but the
velocity of growth was reduced.
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The use of surfactants and the introduction of new res-
piratory therapeutic modalities has changed the outcome
for preterm newborns with respiratory distress syndrome,
even though effects on the incidence of bronchopulmonary
dysplasia (BPD) have not been observed.
Bronchopulmonary dysplasia is one of the main causes
of morbidity in the neonatal intensive care unit (NICU), es-
pecially for very low birth weight infants, with reported
incidences of up to 71% among the newborns with a gesta-
tional age of 25 weeks,1 30% among newborns with a birth
weight under 1500 g,2 and up to 100% for birth weights
between 500 and 750 g.1,3,4
A greater survival of very low birth weight infants with
BPD results in higher costs, especially in for the NICU, in
addition to longer hospital stays and, after the discharge,
frequent re-hospitalizations.
Several clinical trials have described favorable effects
with the use of corticosteroids in the neonatal period, in-
cluding a reduction of the incidence of BPD,5-9 the dura-
tion of mechanical ventilation,6,10-13 and short-term improve-
ment in pulmonary compliance.10,11
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However, concomitant with favorable effects of
corticosteroids in preterm infants who are dependent on
mechanical ventilation, several adverse effects have also
been described such as hyperglycemia,6,13-15 systemic arte-
rial hypertension,10,13-16 interventricular septum hypertro-
phy,5,15,17 irritability,5 gastrointestinal perforation,18 intensi-
fication of prematurity retinopathy ,19 suppression of the
adrenal axis,20 alteration in mineral homeostasis21 and the
bone growth,22 postnatal growth retardation,23,24 and an in-
crease of infection incidence.25
In addition to these short-term adverse effects, a higher
incidence of cerebral palsy and neurological alterations
have been observed in preterm newborns that received
corticosteroids in the neonatal period and underwent long-
term evaluation.26,27
This study analyzed the effects of the use of dexametha-
sone beginning between 10 and 14 days of life in very low
birth weight infants and dependent on mechanical ventila-
tion. We analyzed the incidence of BPD and its evolution,
the duration of mechanical ventilation and oxygen therapy,
the adverse effects and mortality with the purpose of evalu-
ating the hypothesis that this corticosteroid can benefit the
respiratory evolution of these newborns even though its use
also has some adverse effects.
METHODS
A cohort study was performed that included 38 preterm
newborns. These were selected according the the follow-
ing inclusion criteria: gestational age <37 weeks, birth
weight <1500 g, dependence on mechanical ventilation be-
tween the 10th and 14th days of life.
Newborns with congenital malformations and chromo-
somal alterations were excluded, as were newborns who pre-
sented one of the following diagnoses at the beginning of
the study: infection, hyperglycemia, systemic arterial hy-
pertension, or hemorrhagic syndromes.
Newborns selected for the study were divided into 2
groups: Group I — received dexamethasone and Group II
— did not receive dexamethasone.
Dexamethasone was administered to newborns that ful-
filled the inclusion criteria according to the following thera-
peutic schedule beginning on the 10th day of life: every 12
hours, for 9 days as follows: day 1 through 3 — 0.3 mg/kg/
day; day 4 through 6 — 0.2 mg/kg/d; and day 7 through 9
— 0.1 mg/kg/d.
Gestational age was determined from the date of the last
menstruation; this was confirmed by the New Ballard
method.28 When a difference of 2 or more weeks in esti-
mated gestational age occurred between the clinical evalu-
ation through this method and the one determined by the
date of last menstruation, the clinical evaluation was used.
The newborns were classified as adequate for gestational
age (AGA), when their birth weights were below percentile
90 and above percentile 10 of the Ramos Intrauterine
Growth Curve,29 and small for gestational age when their
birth weights were below percentile 10 of that curve.30
The development of BPD was analyzed as the factor of
primary concern. As a secondary concern, the following
were observed: duration of mechanical ventilation and oxy-
gen therapy, mortality, length of stay in the neonatal unit,
neonatal growth pattern during the hospital stay, and the
occurrence of adverse effects including systemic infection,
fungal infection, hyperglycemia, systemic arterial hyperten-
sion, persistence of ductus arteriosus, necrotizing entero-
colitis, intracranial hemorrhage, retinopathy of prematurity,
and metabolic bone disease.
We defined BPD as dependence on oxygen in preterm
newborns at risk at 28 days of life confirmed by clinical
and radiological alterations.31,32
Diagnosis of pneumonia was established in the presence
of clinical deterioration, tachypnea, rales, and radiological
signs of condensation and/or positive blood culture. Infec-
tion was defined as the occurrence of clinical worsening,
poor peripheral perfusion, hypoactivity, and positive blood
culture. Hyperglycemia was defined as a plasma glycemic
level equal to or higher than 150 mg/dL.33 Systemic arte-
rial hypertension was defined as a systolic pressure equal
to or higher than 2 standard deviations from that reference.34
The diagnosis of persistence of ductus arteriosus was based
on the presence of clinical manifestations such as systolic
or continuous murmur in the second left intercostal space,
pulsatile precordium or visible ictus, or wide pulses at the
physical examination and confirmed by the echocardiogram.
The diagnosis of necrotizing enterocolitis was made when
the following clinical alterations were noted: abdominal
distention, bloody stools, pain at abdominal palpation and/
or radiological alterations, distended intestinal loops,
edema in the walls of intestinal loops, and the presence of
pneumatosis intestinalis.35 Diagnosis of intracranial
hemorrhage was based on the result of the head ultrasonog-
raphy as classified according to Papile.36 Perinatal asphyxia
was diagnosed when the newborn presented an Apgar score
<6 at the fifth minute of life.37
A chest x-ray was performed at admission at any time
when clinically indicated, and at 28 days of life; head ul-
trasonography was performed in the first 7 days of life and
at approximately 14 and 30 days of life; an echocardiogram
was performed in the presence of a murmur in the second
left intercostal space or wide pulses with visible ictus were
detected; an ophthalmologic examination was performed
at 4 weeks of life by a pediatric ophthalmologist using the
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international classification.38 The assistance to the newborn
followed the guidelines in the NICU and was prescribed by
the responsible assistant doctor, who was blinded to the
study groups.
For the purposes of statistical analysis, a database was
developed using the EPI-INFO 6.04 software. For continu-
ous variable analysis, the t test and Mann-Whitney test were
used, and for discrete variables, the chi square test was used.
Statistical significance was declared when P <.05.
RESULTS
Among 38 very low birth weight newborn infants ad-
mitted between January 2000 and July 2001 were included,
16 were selected for Group I (dexamethasone treated) and
22 for Group II.
The groups did not differ regarding gestational age, birth
weight, gender, color, size for gestational age, perinatal as-
phyxia, and surfactant administration (Table 1).
A tendency for a higher incidence of BPD occurred in
Group I (Group I — 62.5%, Group II — 22.7%, P = .07).
No effect of the use of dexamethasone on duration of me-
chanical ventilation was observed (Group I — 19 ± 14 days,
Group II — 12.9 ± 10 days, P = .09). However, Group II
used oxygen for a shorter period (Group I — 20 ± 10 days,
Group II — 8 ± 4 days, P = .05).
There was a tendency for reduced mortality in the group
that received dexamethasone (Group I — 6.5%, Group II
— 30%, P = .07). Nevertheless, an influence by the use of
dexamethasone on the hospitalization length was not ob-
served (Group I — 78.5 ± 40 days, Group II — 64.8 ± 26
days, P = .32) (Table 2).
A reduced weight gain and growth velocity of the head
circumference was detected between 28 and 36 weeks of
corrected gestational age in Group I compared with Group
II (change in weight: Group I — 47 g/week and Group II
— 85.5 g/week, P = .06); change in head circumference:
Group I — 0.75 cm/week and Group II — 1 cm/week, P =
.05) (Figure 2). Regarding length, there were no ob-
served differences between the groups (Figure 2).
Weight gain (Figure 1) and growth velocity of the head
circumference (Figure 2) between 28 and 36 weeks of cor-
rected gestational age were reduced in Group 1 as compared
to Group 2: weight gain was 47 g/week in Group I, 85.5 g/
week in Group II, (P = .06); the head circumference increased
by 0.75 cm/week in Group I, vs. 1.00 cm/week in Group II
(P = .05)
DISCUSSION
Corticosteroids have been used with the aim of reduc-
ing the inflammatory responses due to antiinflammatory re-
actions39,40 triggered by several factors, such as hyperoxia,41
infection,42 and mechanical ventilation43,44 among others,
upon the developing lung. These inflammatory responses
may contribute to reduced alveolarization,41-44 which con-
stitutes one of the main characteristics of BPD.45
Favorable effects on the incidence BPD as a result of
the use of corticosteroids in preterm newborns dependent
on mechanical ventilation at 10 to 14 days of life were not
observed in this study. Neither did a reduction of the dura-
tion of ventilation, nor of the hospital stay result from the
use of corticosteroids, in contrast to what has been observed
by others.7,9,10,12,13 However, we found a tendency for re-
duced mortality among newborns that received
corticosteroids as described.7,9,10,12,13 It is possible that be-
cause of the design of the study, in which the inclusion cri-
terion was children dependent on mechanical ventilation
between 10 and 14 days of life, newborns with severe pul-
monary diseases may have been selected for inclusion, and
consequently, evidence of favorable effects of
Table 2 - Adverse effects in the studied groups (%).
Group I Group II P
Pneumonia 62.5 63.6 .95
Bacterial infection 93.0 77.2 .60
Fungal infection 0 4.5 .90
Persistence of ductus arteriosus 50.0 54.5 .95
Interstitial emphysema 25.0 22.0 .99
Necrotizing enterocolitis 6.2 18.1 .37
Hyperglycemia 6.2 0.0 .43
Blood hypertension 0.0 4.5 .99
Gastrointestinal bleeding 0.0 4.5 .99
Intracranial hemorrhage 31.2 9.6 .10
Phosphorous deficiency 37.5 13.6 .12
Table 1 - Characteristics and evolution of the studied
population.
Group I Group II P
Gestational age (wk) 28.9 ± 1.8 29 ± 1.7 .99
Birth weight (g) 1082.18 ± 200 970 ± 264 .29
Gender (M/F) (%) 43.75/56.25 50/50 .95
Color (white/nonwhite) 62.5/37.5 68.2/32.8 .98
Adequate for gestational 68.7 59.0 .78
age (%)
Small for gestational age (%) 31.2 41.0 .78
Perinatal asphyxia (%) 66.6 35.0 .15
Surfactant (%) 93.75 68.2 .13
Hospital stay (d) 78.6 ± 40.2 64.8 ± 26.0 .32
Duration of oxygen 20.1 ± 2.0 8.0 ± 8.2 .05
therapy (d)
Extubation (d) 2.6 ± 2.2 3.0 ± 1.0 .40
Duration of mechanical 19.1 ± 5.0 12.9 ± 10.0 .09
ventilation (d)
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Figure 1 - Evolution of weight of included patients between 36 and 40 weeks of corrected gestational age in children treated with corticosteroids
(Group I - open circles, treatment started at week 32), or untreated (Group II – closed circles). Observed values are compared to the 10, 50, and
90 percentile curves (percentile curves: full lines; smoothed percentile curves: dotted lines).
Figure 2 - Evolution of head circumference of included patients between 36 and 40 weeks of corrected gestational age in children treated with
corticosteroids (Group I - open circles, treatment started at week 32), or untreated (Group II – closed circles). Observed values are compared to
the 10, 50, and 90 percentile curves (percentile curves: full lines; smoothed percentile curves: dotted lines).
corticosteroids upon the respiratory function in this selected
group may not have become evident. However, it is impor-
tant to note that the newborns included in the treated group
had a tendency for a lower mortality rate, which indirectly
could be suggesting that despite the severity of their con-
ditions, certain benefits may have occurred.
Over the past decades, methods have differed as to the
beginning of administration of corticosteroids: (i) from the
first hours of life (early),6,7-9,16,45-47 (ii) from 7 to 14 days of
life (moderately early),12,23,48 (iii) after 14 days of life
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(late)10,13,49,50. Doses and the length of treatment (from 9 to
42 days) are also reported.
Despite this great variability in the method of adminis-
tration of corticosteroids, favorable effects have commonly
been detected. A reduction in the incidence of BPD due to
the therapeutic schedules that started either in the first hours
of life or between the 7th and 14th day of life7,9,48,51 have been
reported, in addition to a reduction in the duration of me-
chanical ventilation and great success with extubation in
all schedules.7,9,48,51,52
Nevertheless, common adverse effects have also been
described in the short-term, such as hyperglyce-
mia,6,9,13,14,15,48,51 systemic arterial hypertension,9,10,13-16,51,52
hypertrophy of the myocardium,5,15,17,51 gastrointestinal
bleeding,9,51 and an elevation in the incidence of infec-
tions.25,51,52
In this study the use of corticosteroids did not alter most
of the factors described above. However, an increase in the in-
cidence of hyperglycemia occurred that was similar to that
found in other studies. In addition, we observed a decrease in
the growth between 28 and 36 weeks of corrected gestational
age. Others have described this influence in the postnatal
growth. Papile et al.23 detected a reduction in the head circum-
ference growth of newborns during corticosteroid therapy.
Mataloun et al.24 observed a decrease in growth during
corticosteroid therapy in a study that used higher doses over
a prolonged period; growth resumed after the suspension
of treatment.
At present, long-term follow-ups of children who re-
ceived corticosteroids during the neonatal period have been
revealing neurological alterations and an increase of the in-
cidence of cerebral palsy.9,52 It is important to emphasize
that these long-term neurological alterations were found in
children who received corticosteroids in the first 96 hours
of life and after 14 days. Additionally, these studies are het-
erogeneous regarding the dosage and length of therapeutic
schedule used. The studies that detected increased incidence
of cerebral palsy were of children who received therapeu-
tic schedules of longer duration. However, Shinwell et al.53
showed a 3-fold increase in the incidence of cerebral palsy
with a therapy schedule beginning early and of short dura-
tion (1 to 3 days) in a multicentric study. These results
showed that neurological effects may also occur following
therapy schedules of short duration.
Based on the literature, the use of corticosteroids in
preterm infants who are dependent on mechanical ventila-
tion and are at risk for development of BPD in the neonatal
period is not advised.54,55
In spite of these recommendations, there are still doubts
regarding the long-term adverse effects of corticosteroid use
due to the fact that these investigations are heterogeneous.
In addition, there is an unsolved contradiction in that the
neurological effects have not been observed during long-
term follow-up when the corticosteroids were introduced be-
tween 10 to 14 days of life. These results raise doubts as to
the inevitability of long-term neurological effects.
Although dexamethasone, the most commonly used cor-
ticosteroid in major studies, produces these side effects,
other corticosteroids such as beclomethasone may not.56
This issue requires further study.
Some neonatal units, including many in Brazil, continue
to use dexamethasone with restricted indications57 despite
existing recommendations. Therefore, new studies to
analyze the neurological evolution of the newborns that re-
ceived corticosteroids in the neonatal period, mainly be-
tween 10 and 14 days of life, is necessary.
The results of this study do not favor the use of
corticosteroids in preterm newborns dependent on mechani-
cal ventilation between 10 and 14 days of life because there
was no evidence of favorable effects upon the respiratory
evolution of these newborns, although a tendency for lower
mortality was detected; on the other hand, unfavorable ef-
fects upon growth were detected.
Moreover, recent investigations regarding the patho-
physiological mechanisms involved in “new” BPD empha-
size the great importance of perinatal development and sug-
gest beginning the use of mechanical ventilation earlier and
continuing for a period longer than 7 days. Therefore, be-
ginning treatment with corticosteroids between 10 and 14
days of life could be too late for prevention of BPD, in ad-
dition to increasing the risk of unfavorable effects on
growth and adverse effects.
RESUMO
MATALOUN MMGB e col. Efeitos de corticosteróides em
recém-nascidos de muito baixo peso, dependentes de
ventilação mecânica. CLINICS 60(2):113-120, 2005.
Devido às suas ações anti-inflamatórias, os corticos-
teróides têm sido utilizados para prevenção de displasia
broncopulmonar, sendo descrita, uma redução da incidên-
cia desta patologia. No entanto, efeitos adversos a curto e
a longo prazo têm sido detectados, em recém-nascidos pré-
termo.
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OBJETIVO: Analisar os efeitos sobre a incidência de
displasia broncopulmonar, duração de ventilação mecâni-
ca e de internação, mortalidade, crescimento, além dos efei-
tos adversos dos corticosteróides, administrados entre
10-14 dias de vida, em recém-nascidos de muito baixo peso,
dependentes de ventilação mecânica.
MÉTODOS: Realizou-se estudo de coorte, incluindo-
se todos os recém-nascidos com peso de nascimento < 1500
gramas dependentes de ventilação mecânica, entre 10-14
dias de vida. Foram divididos em: Grupo I – receberam
dexametasona (16) e Grupo II – não receberam dexa-
metasona (22). Administrou-se dexametasona, a partir do
10º dia de vida, dias 1 a 3 – 0,3 mg/kg/d, dias 4 a 6 – 0,2
mg/kg/d, dias 7 a 9 – 0,1 mg/kg/d. Analisou-se o desenvol-
vimento de displasia broncopulmonar (dependência de oxi-
gênio aos 28 dias de vida), efeitos sobre a evolução respi-
ratória e sobre o padrão de crescimento, além da ocorrên-
cia de efeitos adversos.
RESULTADOS: A incidência de displasia broncopul-
monar não diferiu entre os grupos (GI – 62,5%; GII –
22,7%;p = 0,07). Detectou-se desaceleração do crescimen-
to no GI em relação ao GII(D P = 47g/semana, GI e 85,5g/
semana, GII; p = 0,06; D PC – 0,75 cm/semana GI e 1cm/
semana, no GII; p = 0,05).
CONCLUSÃO: O uso de corticosteróides, em recém-nas-
cidos pré-termo, entre 10 – 14 dias de vida não reduziu in-
cidência de displasia broncopulmonar e causou uma
desaceleração do crescimento.
UNITERMOS: Corticosteróides. Recém-nascido pre-
maturo. Displasia broncopulmonar.
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